Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Italiano

Showing results (101-110 of 133) with videos related to

Pageof 14
Sort By:
ESMO Open|June 13, 2025
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)V Gambardella, M K Accordino, P L Bedard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2021
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)<sup>☆</sup>P G Casali, A Le Cesne, A P Velasco, et al.
ESMO Open|May 9, 2022
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 studyC Baldini, E Charton, E Schultz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2022
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitorsF Peyraud, J-P Guégan, D Bodet, et al.
ESMO Open|February 24, 2022
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)C Moreau-Bachelard, L Campion, M Toulmonde, et al.
ESMO Open|August 3, 2023
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 studyE Charton, C Baldini, Y Fayet, et al.
Scientific Reports|October 12, 2019
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell TumorF G M Verspoor, M J L Mastboom, G Hannink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2021
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trialA Le Cesne, J-Y Blay, D Cupissol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancersJ van de Haar, P Roepman, F Andre, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Codon-specific <i>KRAS</i> mutations predict survival in advanced pancreatic cancerA Boilève, A Rousseau, M Hilmi, et al.
Pageof 14

Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
ESMO Open|June 13, 2025
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)V Gambardella, M K Accordino, P L Bedard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2021
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)<sup>☆</sup>P G Casali, A Le Cesne, A P Velasco, et al.
ESMO Open|May 9, 2022
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 studyC Baldini, E Charton, E Schultz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2022
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitorsF Peyraud, J-P Guégan, D Bodet, et al.
ESMO Open|February 24, 2022
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)C Moreau-Bachelard, L Campion, M Toulmonde, et al.
ESMO Open|August 3, 2023
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 studyE Charton, C Baldini, Y Fayet, et al.
Scientific Reports|October 12, 2019
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell TumorF G M Verspoor, M J L Mastboom, G Hannink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2021
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trialA Le Cesne, J-Y Blay, D Cupissol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancersJ van de Haar, P Roepman, F Andre, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Codon-specific <i>KRAS</i> mutations predict survival in advanced pancreatic cancerA Boilève, A Rousseau, M Hilmi, et al.
Pageof 14